ABVX
Abivax SA American Depositary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.73B
P/E Ratio
—
EPS
$-5.59
Beta
-0.10
52W High
$148.83
52W Low
$4.77
50-Day MA
$117.61
200-Day MA
$92.66
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Abivax SA American Depositary Shares
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections, with its lead candidate ABX464 currently in clinical trials for ulcerative colitis and other indications. The company’s innovative approach integrates antibody-mediated therapies with proprietary compounds, targeting significant unmet medical needs in the healthcare market. With a robust pipeline and a dedicated scientific team, Abivax stands as an intriguing investment opportunity for institutional investors seeking to engage in the burgeoning immunotherapy sector.
Fundamentals
| Revenue (TTM) | $4.57M |
| Gross Profit (TTM) | $4.57M |
| EBITDA | $-244.98M |
| Operating Margin | -3743.00% |
| Return on Equity | -135.60% |
| Return on Assets | -39.00% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $6.71 |
| Price-to-Book | 17.79 |
| Price-to-Sales (TTM) | 2128.36 |
| EV/Revenue | 157.63 |
| EV/EBITDA | -12.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -55.40% |
| Shares Outstanding | $79.29M |
| Float | $64.14M |
| % Insiders | 0.00% |
| % Institutions | 84.18% |
Analyst Ratings
Consensus ($155.20 target)
4
Strong Buy6
BuyData last updated: 4/7/2026